The ubiquity of toxin/antitoxin (TA) systems in Archaea[@b1] and Bacteria[@b2] appears to be counterintuitive given the cornerstone of Darwinian evolution of increased fitness through natural selection[@b3]. TA systems consist of toxic proteins that disrupt cellular processes along with labile antitoxins that counteract this growth inhibition. Without stress, antitoxins mask the toxins and growth is rapid. However, during environmental stress, antitoxins are degraded more rapidly[@b4][@b5], and toxins are activated. This toxin-mediated reduced growth is therefore beneficial for bacteria for surviving antibiotic stress[@b6][@b7][@b8] and for combating phage attack[@b9]. Hence, TA systems have evolved to serve physiological needs[@b10].

TA systems can be found in mobile genetic elements (e.g., plasmids) and in chromosomes. The role of plasmid-derived TA systems in stabilizing plasmid copies has been clear since their first discovery[@b11]; however, the role of chromosomal-derived TA systems has slowly become more evident over the past three decades. Chromosomal TA systems are involved in tolerance to antibiotics[@b6][@b7][@b8], biofilm formation[@b12][@b13][@b14], host colonization[@b15], survival[@b16], and pathogenicity[@b17][@b18]. TA systems are also involved in elegant cellular regulation of genes other than their own loci including direct control of another TA system[@b19], selective protein enrichment[@b20][@b21], and the general stress response[@b4][@b5].

Given the functional diversities of toxins and antitoxins[@b22], it appears that individual components have been recruited independently from the genetic/proteomic pool to form new TA pairs. For instance, the GhoS antitoxin is homologous to the Cas2 protein from the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated proteins) system[@b23]. In the IetS/IetA system, the IetS toxin is highly similar to subtilisin-like serine proteases while the IetA antitoxin is similar to AAA-ATPases[@b24]. Mruk and Kobayashi also speculated, based on similarities in genetic structures, biological functions, and regulatory mechanisms, that TA systems and restriction-modification systems may be related[@b25]. Furthermore, there are at least 12 toxins/antitoxins acting as endoribonucleases in *E. coli*[@b23][@b26], but not all of these are homologs, which means that these toxins/antitoxins must have arisen and assembled at separate times. These observations suggest functional overlap between TA modules and other proteins, and raise the question whether a *de novo* TA system can be built using extant protein components.

To explore the impact of evolution on TA systems and their physiological role in their host, we set out to test whether one of the most extreme changes in a TA system could occur; i.e., whether an antitoxin could be converted into a toxin. Our hypothesis is that existing components of TA systems are molecularly malleable, and thus, may be used to form novel TA pairs. We found that an antitoxin may be converted into a potent toxin with only two amino acid changes and that two disparate antitoxins (a protein and an RNA) may be created that mask the toxicity of this novel toxin. We refer to this new toxin as ArT ([ar]{.ul}tificial [t]{.ul}oxin) and the antitoxins as ArA and ArA\* ([ar]{.ul}tificial [a]{.ul}ntitoxin).

Results
=======

TA systems are classified as type I when the RNA antitoxin inhibits the toxin mRNA, type II when the protein antitoxin inhibits the toxin protein, type III when the RNA antitoxin inhibits the toxin protein, type IV when the protein antitoxin shields the substrate from the toxin protein, and type V when the protein antitoxin degrades the toxin mRNA[@b27]. To synthesize a *de novo* artificial TA system, we used components from well-studied TA systems of different classes as starting materials: to create the toxin ArT, we started with type V antitoxin GhoS of the *E. coli* GhoT/GhoS TA system[@b19][@b23] and to create the antitoxins using two different approaches, we started with type II antitoxin MqsA of the *E. coli* MqsR/MqsA TA system[@b4][@b28] and type III antitoxin ToxI of the *Erwinia carotovora* subspecies *atroseptica* (also known as *Pectobacterium atrosepticum*) ToxN/ToxI system[@b29]. Error-prone PCR (epPCR) was employed as a means of introducing random mutations into the genes of these disparate components, and the impact on antibiotic persistence was used to assay the impact of the artificial TA module.

Random mutagenesis of *ghoS* to form artificial toxin ArT
---------------------------------------------------------

GhoS is an antitoxin endoribonuclease that specifically cleaves the mRNA of toxin GhoT along with 20 mRNAs encoding proteins involved in purine or pyrimidine transport and biosynthesis[@b23]. GhoS is not toxic to *E. coli* and increases growth slightly when overproduced[@b23]. To create ArT, GhoS variants were selected based on reduced growth.

A plasmid library containing \~2 × 10^5^ mutated GhoS variants was generated using epPCR with an error rate of 1.2%. In this plasmid library, all GhoS variants were expressed from an IPTG-inducible *T5-lac* promoter in pCA24N[@b30]. After transforming a *ghoS* deletion *E. coli* strain (BW25113 Δ*ghoS*) with this library (to prevent interference by native GhoS), colonies of different size appeared in the absence of IPTG, indicating that the growth of the cells producing these GhoS variants was not uniform and that the basal level of expression of mutated GhoS was sufficient to result in impaired growth. We picked \~2,800 small colonies from this library, and the 10 colonies that grew the slowest on IPTG-containing agar were chosen for sequencing. Although these 10 GhoS variants harbor substitutions at various residues, four residues (D15, M31, E43, and N85) were repeatedly substituted ([Fig. S1](#s1){ref-type="supplementary-material"}), and may be important for controlling the activity of GhoS. In particular, the M31L and L25I substitutions alone reduced colony formation of *E. coli* ([Fig. 1a](#f1){ref-type="fig"}). Growth toxicity was further increased when L25I was introduced into GhoS-M31L to form GhoS-L25I-M31L (termed as ArT hereafter). Colony formation in cells expressing ArT was inhibited ([Fig. 1a](#f1){ref-type="fig"}), and the growth of ArT-expressing strain in LB was reduced to a level comparable to the inhibitory effect of toxin GhoT ([Fig. 1b](#f1){ref-type="fig"}). Therefore, antitoxin GhoS was converted successfully into toxin ArT.

ArT is independent of GhoT and MqsR and causes ghost-cell formation
-------------------------------------------------------------------

We investigated whether the toxicity of ArT depends on either toxin GhoT or toxin MqsR; MqsR, the toxin from the MqsR/MqsA system, activates GhoT by cleaving the mRNA of *ghoS*[@b19]. When ArT was produced in a *ghoT*-deleted strain (BW25113 Δ*ghoT*), ArT remained toxic ([Fig. S2](#s1){ref-type="supplementary-material"}). Moreover, when ArT was produced in an *mqsRA* deletion strain (BW25113 Δ*mqsRA*), ArT remained toxic ([Fig. S3](#s1){ref-type="supplementary-material"}). Hence, the toxicity of ArT is novel and it is independent of toxins MqsR and GhoT.

Microscopy was performed to investigate the mechanism of ArT toxicity via morphological changes. Microscopic examination has been used to reveal morphological changes brought about by toxin expression; for example, GhoT-producing cells often appear as "ghost" cells[@b23]. Similar to the effects of GhoT, we found that producing ArT causes cells to become "ghost"-like ([Fig. 2a](#f2){ref-type="fig"}). This phenotype was further supported by transmission electron microscopy images of cells producing ArT, in that the center of the cells became translucent (red arrow, [Fig. 3b](#f3){ref-type="fig"} and [Fig. 3e](#f3){ref-type="fig"}), and the surrounding area (cytoplasm) became darker, with the darkest spots at cell poles (green circles, [Fig. 3b](#f3){ref-type="fig"}). Such translucent centers are compact nucleoids that typically appear when growth is suppressed, such as in the event of translation inhibition[@b31]. In contrast, true "ghost" cells resemble an empty nest with cytoplasmic regions condensed at the cell poles ([Fig. 3c](#f3){ref-type="fig"}). Unlike cells producing GhoT, cell lysis or breakage was not observed in ArT-producing cells. Using GFP-tagged ArT and fluorescence microscopy, we found that ArT is localized throughout the cells, while GFP-tagged GhoT specifically localized at the cell poles ([Fig. 2b](#f2){ref-type="fig"}). Therefore, ArT causes cells to become "ghost"-like but not to the same extent as GhoT.

Five catalytic residues are conserved in GhoS ([Fig. S1](#s1){ref-type="supplementary-material"}) and its structural homolog, Cas2, from the CRISPR-Cas system, with R28 being the most important residue for the endoribonuclease activity of GhoS[@b23]. In ArT, mutations L25I and M31L are located very close to R28 ([Fig. 1c](#f1){ref-type="fig"}), and they may affect the catalytic activity of GhoS. To gain further insights into mechanism of toxicity of ArT, whole-transcriptome studies were conducted for cells producing GhoS and ArT. In comparison to cells harboring an empty plasmid, 20 gene transcripts were degraded upon production of native GhoS[@b23]. Among these, four transcripts (*purE*, *purH*, *purM,* and *purT*) were also degraded in the ArT-producing strain. However, 48 additional transcripts were degraded in cells overproducing ArT compared to those overproducing GhoS. No transcripts were significantly enriched in cells that produce native GhoS, but 19 transcripts were enriched in cells that produce ArT ([Supplemental Table 1](#s1){ref-type="supplementary-material"}). These results suggest that ArT has become an endoribonuclease with a broader substrate range.

Random mutagenesis of *mqsA* to form artificial antitoxin ArA
-------------------------------------------------------------

To investigate whether antitoxin activity toward ArT may be readily generated from antitoxins that are not related to ArT, we created MqsA variants via epPCR. MqsA was chosen because the regulation and function of this antitoxin have been well studied[@b4][@b28][@b32][@b33]. MqsA has two domains: the toxin protein-binding domain at the N-terminus and the DNA-binding domain at the C-terminus[@b28][@b33]. To prevent interference with the DNA-binding activity of MqsA, we mutagenized only the protein-binding domain at the N-terminus (residues 1 to 76). We introduced a C→T DNA substitution at L81 (silent mutation) to create a *Hind*III site downstream of the N-terminal domain in order to facilitate mutagenesis of the N-terminal domain. The entire *mqsA* gene was then placed downstream of *ghoS-M31L* (in pCA24N-*ghoS-M31L*), which encodes the toxic GhoS-M31L variant ([Fig. 1b](#f1){ref-type="fig"}). Hence, MqsA variants could be selected based on their ability to reduce the severe growth inhibition of GhoS-M31L with both GhoS-M31L and the MqsA variants produced from the same IPTG-induced promoter. Note that native MqsA is not toxic and does not decrease the toxicity of GhoS-M31L ([Fig. 4a and 4b](#f4){ref-type="fig"}), and that we initiated the experiments to find an antitoxin for the GhoS-M31L toxin variant since we had this variant before we obtained GhoS-L25I-M31L (ArT).

We generated a plasmid library of mutated *mqsA* using epPCR at a 1.7% error rate, and used this library to transform *E. coli* with both *ghoS* and *mqsRA* deleted (to prevent interference from the native proteins). Among the 4.2 × 10^8^ MqsA variants screened, six MqsA variants were identified as putative antitoxins for GhoS-M31L, as they were able to alleviate the toxicity of GhoS-M31L in the presence of IPTG, and the cells grew as well as the wild-type strain ([Fig. 4a and 4b](#f4){ref-type="fig"}). Four residues (K2, H7, D51, and M54) were mutated in more than one MqsA variant ([Fig. S4](#s1){ref-type="supplementary-material"}), which suggests that these mutations were responsible for conferring the improved growth phenotype. We confirmed that in these six MqsA variants, both GhoS-M31L and MqsA variants were co-produced in the cells ([Fig. S5](#s1){ref-type="supplementary-material"}). Among these six MqsA variants, we chose MqsA variant MP22 (F22L, C37S, D51N, and F60L, referred to as ArA hereafter) for further analyses.

To investigate whether ArT toxin and ArA antitoxin interact *in vivo*, we performed a bacterial two-hybrid assay. We cloned *arT* and *arA* separately into two plasmids, with each expressing one domain of adenylate cyclase[@b34]. If two proteins of interest physically interact, the host forms a blue colony on reporter plates as was found for the positive control ([Fig. S6](#s1){ref-type="supplementary-material"}). However, no *in vivo* interaction was observed for ArT and ArA, as indicated by a lack of blue colonies on reporter plates ([Fig. S6](#s1){ref-type="supplementary-material"}).

Random mutagenesis of *toxI* to form artificial antitoxin ArA\*
---------------------------------------------------------------

Given that type II antitoxin MqsA could be converted into a protein that reduces ArT toxicity, we investigated whether we could evolve a second antitoxin for ArT using an RNA-based antitoxin (type III system). We chose ToxI, which is the antitoxin from the ToxIN system[@b29]. The RNA-coding region of *toxI* is made up of 5.5 direct repeats, with each repeat consisting of 36 nt (5′-AGGTGATTTGCTACCTTTAAGTGCAGCTAGAAATTC-3′). We placed *toxI* under the control of a *lac* promoter and without a ribosome binding site, and cloned this P*~LlacO-1~*::*toxI* fragment into pCA24N-*arT*. We generated a plasmid library of mutated *toxI* using epPCR with a 1% error rate. Similar to the screening strategy used for selecting MqsA variants, we screened for improved growth when ArT was produced along with various ToxI transcripts. Six strains with *toxI* mutations that completely abolished the toxicity of ArT were isolated ([Fig. 5](#f5){ref-type="fig"}). For each *toxI* variant, there were 1-6 nucleotide substitutions in the RNA-coding region ([Fig. S7](#s1){ref-type="supplementary-material"}). Nucleotide substitutions were found in every repeat, except for the 3^rd^ repeat. Overall, the toxicity of ArT could be readily counteracted by artificially evolved antitoxins generated from an unrelated protein (MqsA) to form the basis of a novel type II TA system and from unrelated RNA (ToxI) to form the basis of a novel type III TA system.

Transcriptional control in the artificial TA system
---------------------------------------------------

For type II TA systems, antitoxins typically harbor a DNA-binding domain that allows them to act as transcriptional regulators. For example, MqsA represses *mqsRA* expression by binding its cognate binding site, the two palindromes in its promoter[@b35]. Such transcriptional self-regulation by the antitoxin is canonical for type II TA systems. Hence, we investigated whether the ArT/ArA system could be engineered to be regulated in a similar manner. Given that MqsA binds specific palindromic DNA motif \[5′-[AACCT]{.ul} (N)~3~ [AGGTT]{.ul}-3′\], we cloned the two *mqsRA* palindromes into the synthetic *T5-lac* promoter in pCA24N to form *P~T5-lac-pals~* ([Fig. S8](#s1){ref-type="supplementary-material"}), and tested whether ArA would be able to repress *arT* expression by binding to the palindromes. To demonstrate *arT* repression by ArA, we measured *arT* transcription from *P~T5-lac-pals~* using quantitative real-time reverse-transcription PCR (qRT-PCR) upon ArA production from a *P~ARA~* promoter on a separate plasmid ([Fig. S9](#s1){ref-type="supplementary-material"}). In comparison to the empty pBAD plasmid control (*arT* expression set as 100%), MqsA production via pBAD-*mqsA* reduced *arT* expression by 63 ± 18%, while ArA production via pBAD-*arA* reduced *arT* expression by 40 ± 15%. Therefore, similar to native MqsA, ArA binds *P~T5-lac-pals~* to repress the expression of toxin.

Final constructs
----------------

Since transcription from *P~T5-lac-pals~* can be controlled by ArA, we subsequently placed *ArT*, *ArA*, and *ArT+ArA* under the control of this promoter. The resulting plasmids are termed as pCA24N-*arT* ([ar]{.ul}tificial [t]{.ul}oxin), pCA24N-*arA* ([ar]{.ul}tificial [a]{.ul}ntitoxin), and pCA24N-*arTA* ([ar]{.ul}tificial [t]{.ul}oxin/[a]{.ul}ntitoxin). We re-tested the toxicity of these final constructs in the presence of IPTG, and found that the additional palindromes had minimal effect on the toxicity of ArT, or antitoxicity of ArA ([Fig. S10](#s1){ref-type="supplementary-material"}).

Persistence to ampicillin
-------------------------

Many toxins, such as MqsR, increase persistence to antibiotics[@b6]. Therefore, we measured the persistence level of ArT-expressing cells. In comparison to cells harboring an empty vector, ArT increased persistence to ampicillin by 10^4^ fold ([Fig. 6](#f6){ref-type="fig"}), and this persistence level was only \~2-fold less than MqsR. Note that the persistence level shown by GhoS-expressing cells was not significantly higher than that of the empty vector. In comparison to ArT alone, cells producing both ArT and ArA (with antitoxin ArA masking toxicity of ArT) had 65 ± 20-fold less of an impact on persistence compared to ArT. This shows that ArT is a *bona fide* toxin, and ArA is an antitoxin that masks the toxicity of ArT.

Discussion
==========

In this study, we demonstrate that TA systems evolve readily since we showed that the components of a TA system can be made by evolving existing TA components of different classes. To form a toxin, we converted a native antitoxin to a protein that inhibits growth (ArT) by introducing only two substitutions. To form antitoxins for the novel ArT toxin, we evolved a protein (MqsA to form ArA) as well as evolved a non-coding RNA (ToxI RNA to form ArA\*). To form ArA, only four amino acid substitutions were required ([Fig. S4](#s1){ref-type="supplementary-material"}), and to form ArA\*, as few as one nt change was required ([Fig. S7](#s1){ref-type="supplementary-material"}). Therefore, collectively, our results show that TA components are functionally plastic and may be interchanged to generate new systems.

Our results fit well with previous results that have shown that a handful of amino acid substitutions can impact toxin and antitoxin activity. For example, two simultaneous amino acid substitutions (G22S and D291A) abolished the toxicity of HipA (from the HipA/HipB TA system), although this variant still conferred a high persistence phenotype similar to native HipA[@b36]. A D83Y substitution also relaxed the interaction specificity between the type II Txe/Axe system that allows the Txe toxin to interact with the YefM antitoxin (from the YoeB/YefM TA system)[@b37]. Also, TA systems have been exploited for biotechnological purposes such as the evolution of hemolysin expression-modulating protein (Hha) for biofilm dispersal[@b38].

The five known types of TA systems illustrate the diversity of the molecular mechanisms of TA systems[@b22], especially on how antitoxins counteract the effect of toxins[@b27]. Given that we used GhoS (from a type V TA system)[@b23] and MqsA (from a type II TA system)[@b28] as the starting materials for building an artificial TA system, there were two possible mechanisms by which ArA negates the activity of ArT. Firstly, it was possible that ArA sequestered ArT through direct physical interaction, as how MqsA counteracts the activity of MqsR. However, we showed using bacterial two-hybrid assay that ArA does not interact with ArT. Secondly, the toxicity of ArT might be mediated by either MqsR or GhoT, as shown by the type V TA system (MqsR toxin cleaves the *ghoS* mRNA transcript, and indirectly enriches *ghoT* mRNA), and ArA production might reduce MqsR and GhoT production. However, the toxicity of ArT is not dependent upon GhoT or MqsR ([Fig. S2 and S3](#s1){ref-type="supplementary-material"}), and thus, ArA does not reduce the toxicity of ArT in an MqsR-dependent manner. Overall, these results suggest that TA systems, whether artificial or natural, may exert their effects in a manner that is yet to be fully understood.

One question that has puzzled the TA field is why cells have many TA systems. For example, *E. coli* has 38 TA systems[@b23][@b39] and *Mycobacterium tuberculosis* has 88 TA systems[@b40]. Given the plasticity that we demonstrate here in TA systems, it is tempting to ponder whether one of the primary functions of TA systems is to help cells respond to a myriad of stresses. For example, the MqsR/MqsA TA system is activated by oxidative stress[@b4], the RelE/RelB TA system is activated under nutrient starvation conditions[@b41], and we have recently identified a TA system in *E. coli* that is activated by stress related to exposure to bile acid (Kwan BK and Wood TK, unpublished result). Hence, our results suggest that the cells may co-opt a particular toxin and antitoxin and evolve them to allow the cell to respond to a specific stress.

If our hypothesis is correct, one must consider the source of the building blocks of these new TA systems. Given that the average cell has 3.8 type II chromosomal TA systems[@b27], one likely source for these new TA systems are the existing TA systems found in most genomes. Furthermore, phages are another source of proteins that may be utilized to create new TA systems. Many bacteriophages rely on lytic proteins such as holins and murein hydrolase to lyse the cell[@b42], and these proteins are reminiscent of toxins that disrupt cell membrane and cell wall synthesis such as GhoT[@b8] and PezT[@b43]. For example, the cryptic prophages of *E. coli* now encode at least five TA systems: CbtA/CbeA from CP4-44 prophage[@b44], RelB/RelE[@b45] from Qin prophage, RnlA/RnlB[@b46] from CP4-57 prophage, YpjF/YfjZ[@b47] from CP4-57 prophage, and YkfI/YafW[@b47] from CP4-6 prophage. These five systems may have been created by the host over millions of years by evolving a toxin of the phage, or the phage themselves may have brought an intact TA system. Therefore, TA components may be evolved and their building blocks are readily available.

Methods
=======

Bacterial strains, plasmids, culture conditions, and oligonucleotides
---------------------------------------------------------------------

All strains and plasmids used in this study are summarized in [Table 1](#t1){ref-type="table"}. All strains were grown in lysogeny broth (LB)[@b48] at 37°C, unless indicated otherwise. Kanamycin (50 μg/mL) was used to maintain the Keio strains[@b49], pBS(Kan)-based plasmids[@b50], and pKT25linker-derived plasmids[@b34] ([Table 1](#t1){ref-type="table"}). Chloramphenicol (30 μg/mL) was used to maintain pCA24N-based plasmids[@b30]. Ampicillin (100 μg/mL) was used to maintain pCP20[@b51] and pUT18Clinker-based plasmids[@b34] ([Table 1](#t1){ref-type="table"}). Mutations L25I and M31L were introduced into pCA24N-*ghoS* using mutagenic primers to form pCA24N-*ghoS-L25I*, pCA24N-*ghoS-M31L*, and pCA24N-*arT*. *E. coli* BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^ was created by eliminating the Km^R^ cassette in the BW25113 Δ*ghoS* Δ*mqsRA* Ω Km^R^ strain[@b19]. The *mqsR*-f and *ygiS*-r primers were used to verify the Km^R^ deletion. All plasmids were verified by DNA sequencing. All oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA), and primer sequences are listed in [Supplemental Table 2](#s1){ref-type="supplementary-material"}.

Toxicity tests on solid and liquid media
----------------------------------------

To investigate the effect of toxic protein production on solid media, at least three independent colonies of each tested strain (harboring different pCA24N-derived plasmids) were streaked on LB-chloramphenicol agar with and without 1 mM IPTG. For growth in liquid media, the OD~600~ of every culture was monitored every 1 to 2 h. Overnight cultures of each strain were inoculated into 25 mL LB-chloramphenicol to an OD~600~ of 0.05, grown to an OD~600~ of 0.1, and 1 mM IPTG was added to induce toxic protein production.

Random mutagenesis of *ghoS* and toxicity screening
---------------------------------------------------

*ghoS* from plasmid pCA24N-*ghoS* under the control of the *T5-lac* promoter was mutated under error-prone conditions (0.5 mM Mn^2+^ and 5 mM Mg^2+^)[@b52] using primers pCA24Nf-SH and pCA24Nr-SH. The epPCR product was ligated into the *Xho*I and *Hind*III sites of pCA24N, electroporated into *E. coli* BW25113 Δ*ghoS*, and transformed cells were grown on LB-chloramphenicol agar for 16 h. To screen GhoS variants for increased toxicity (*i.e.*, reduced growth), small colonies (≤0.5 mm in diameter) were picked and transferred onto fresh LB-chloramphenicol agar plates with and without 1 mM IPTG. BW25113 Δ*ghoS* with empty pCA24N, pCA24N-*ghoS* (native GhoS), and pCA24N-*ghoT* (GhoT) were tested alongside as the negative and positive controls. Colonies that showed growth on 0 mM IPTG plates, but no growth on 1 mM IPTG plates, were considered as putative positive hits. To confirm the toxicity was due to substituted GhoS, plasmids were isolated from these putative positive clones, verified by DNA sequencing, and re-electroporated into fresh BW25113 Δ*ghoS* cells for further toxicity tests on solid and liquid media.

Random mutagenesis of *mqsA* and antitoxicity screening
-------------------------------------------------------

As we wished to mutagenize only the N-terminus (the protein-binding domain, residues 1 to 76) of *mqsA* (*mqsA-N*), a C→T silent mutation was introduced to residue L81 of MqsA \[from pBS(Kan)-*mqsA*[@b32]\] using mutagenic primers *mqsA-N*-f and *mqsA-N*-r to create a *Hind*III site. We then cloned the entire *mqsA* coding sequence (with the *Hind*III site) downstream of *ghoS-M31L* (in pCA24N-*ghoS-M31L*) using the *ArA*-f and *ArA*-r primers (that contain an *Acc*I and *Blp*I site, respectively). A FLAG tag (DYKDDDDK) was also fused to the C-terminal domain of MqsA *via* the *ArA-*r primer. The resulting plasmid is pCA24N-*ghoS-M31L*-*mqsA*.

Using the *ArA*-f and *ArA*-r primers, *mqsA-N* was randomly mutated using epPCR as described above. Mutated *mqsA-N* inserts were digested with *Acc*I and *Hind*III, and cloned into *Acc*I/*Hind*III-linearized pCA24N-*ghoS-M31L*. Ligated product was electroporated into BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^. To select for reduced growth toxicity, half of the electroporated population was plated directly on LB-chloramphenicol agar with 1 mM IPTG, and variants that gave rise to large colonies (≥0.5 mm in diameter) were chosen for DNA sequencing analysis and retransformation tests. The other half of the population was plated on LB-chloramphenicol agar (without IPTG), and recovered colonies were pooled with fresh LB-chloramphenicol. Approximately 4.2 × 10^8^ cells were then pre-grown in 50 mL LB-chloramphenicol with 1 mM IPTG for 4 h, and aliquots were plated on LB-chloramphenicol agar with 1 mM IPTG. Similarly, large colonies were chosen for DNA sequencing analysis and retransformation tests.

Random mutagenesis of *toxI* and antitoxicity screening
-------------------------------------------------------

The template for epPCR of *toxI* was pCA24N-*toxI*-*arT*. This plasmid was created by cloning the P*~LlacO-1~*::*toxI* fragment into the *Xho*I site of pCA24N-*arT via* the use of *toxIep*-f and *toxIep-*r2 primers. P*~LlacO-1~* is an RBS-less promoter from pBR-plac[@b53]. The full-length *toxI* including its transcriptional terminator (264 bp; Genbank accession: FJ176937) was fused to P*~LlacO-1~* using primers *toxI*-f and *toxI*-r.

EpPCR for *toxI* was performed as described above using primers *toxIep-*f and *toxIep*-r2. Mutated *toxI* inserts were cloned into the *Xho*I site of pCA24N-*arT*, and ligated product was used to transform BW25113 Δ*ghoS* via electroporation. Electroporated cells were grown in 1 mL LB-chloramphenicol-kanamycin with 0.1, 0.5, or 1.0 mM IPTG for 16 h, followed by plating on LB-chloramphenicol-kanamycin agar with 1 mM IPTG. The resulting large colonies were chosen for DNA sequencing analysis and retransformation tests.

Autoregulation of TA system
---------------------------

To regulate the expression of *ArT* and *ArA* through ArA, a *T5-lac* promoter containing two *mqsRA* palindromes was synthesized (GeneArt, Life Technologies), and termed as P*~T5-lac-pals~*. In *E. coli* K-12 MG1655 (Genbank accession number: U00096.2), the *mqsRA* palindrome 1 is located at position 3166595 bp to 3166609 bp, while *mqsRA* palindrome 2 is located at position 3166629 bp to 3166639 bp. The P*~T5-lac-pals~* cassette was cloned in between *lacO2* and the RBS of pCA24N-*arT* and pCA24N-*arT-arA* using *Xho*I and *BbvC*I. The *BbvC*I site was pre-introduced into the plasmids using the mutagenic primers pCA24N-*BbvC*I-f and pCA24N-*BbvC*I-r. The resulting plasmids were pCA24N-*arT* and pCA24N-*arTA*. To construct pCA24N-*arA*, the NoArT-f and NoArT-r primers were used to amplify the plasmid backbone (without *arT*) of pCA24N-*arTA*. The amplified product was allowed to self-ligate using T4 DNA ligase, before being electroporated into BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^.

TA regulation mediated by ArA
-----------------------------

To evaluate the repression of transcription of *arT* by ArA, *arA* was cloned into the *Nco*I and *Xba*I sites of pBAD-*myc*-His B (Life Technologies) using primers *ArA*-*Nco*I-f2 and *ArA*-*Xba*I-r. Ligated product was introduced into BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^/pCA24N-*arT* via electroporation. As a positive control, pBAD-*mqsA* was also constructed in a similar manner, and electroporated into the same strain. For the negative control, pBAD-*myc*-His B (which expresses only the *myc* epitope and His tag) was electroporated into the same strain.

Independent cultures of the three strains (BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^/pCA24N-*arT* with either pBAD-*arA*, pBAD-*mqsA*, or pBAD-*myc*-His B) were grown in LB-chloramphenicol-ampicillin to an OD~600~ of 0.5, and 1% [l]{.smallcaps}-arabinose was added to induce production of MqsA or ArA. Cells were harvested after 30 min of induction, and total RNA was isolated as described in the following section. qRT-PCR was performed according to manufacturer\'s instructions (*Power* SYBR Green RNA-to-C~[T]{.smallcaps}~ *1-Step* kit, Life Technologies, Carlsbad, CA) using 100 ng of total RNA as the template. Primers were annealed at 60°C, and the housekeeping *rrsG* (16S rRNA) gene was used to normalize all data. Changes in gene transcripts were calculated using the 2^−ΔΔC[t]{.smallcaps}^ formula[@b54].

RNA isolation and whole-transcriptome analysis
----------------------------------------------

Total RNA isolation and DNA microarray analysis were performed as described previously[@b23]. RNeasy Mini kit (Qiagen Inc., Valencia, CA) was used to isolate total RNA from *E. coli* BW25113/pCA24N-*arT* and BW25113/pCA24N after 1 mM IPTG induction for 90 min. Cells were lysed with 0.1 mm zirconia/silica beads (Biospec, Bartlesville, OK). cDNA synthesis, fragmentation, and hybridization to *E. coli* GeneChip Genome 2.0 arrays (Affymetrix, P/N 511302) were performed according to previous protocols[@b20]. Changes in gene expression were considered significant only when they were 5 fold or more. The gene expression data are accessible through GEO accession number GSE54271.

Microscopy
----------

Strains harboring different pCA24N-based plasmids were grown in LB-chloramphenicol to an OD~600~ of 0.5, and production of GhoS, ArT, or GhoT was induced by 1 mM IPTG. Cells were collected after 4 h, washed, and resuspended in 0.85% (w/v) NaCl. Cells were then examined at 1,000× magnification using oil immersion under phase contrast and GFP epifluorescence settings on a light microscope (Zeiss Axio Scope.A1, Germany). Microscopy images were processed using ImageJ[@b55].

Transmission electron microscopy (TEM)
--------------------------------------

Strains (BW25113/pCA24N-*ghoS*, BW25113/pCA24N-*ghoT*, and BW25113/pCA24N-*arT*) were grown in LB-chloramphenicol to an OD~600~ of 0.5, and 1 mM IPTG was added to induce protein production from plasmids. After 4 h of induction, cells were fixed with 2.5% formaldehyde and 1.5% glutaraldehyde in 100 mM sodium cacodylate buffer (pH 7.4) at 4°C for 12 h, followed by three washes with buffer alone for 5 min each wash. Cells were then fixed with 1% osmium tetroxide for 1 h in the dark, followed by three washes with buffer. After treating the cells with 2% uranyl acetate in the dark for 1 h, cells were sequentially dehydrated in a graded ethanol series (50%, 70%, 85%, 95%, and three times with 100% ethanol, for 5 min each) and 100% acetone (three times for 5 min each). Dehydrated cells were embedded into epoxy resins for at least 12 h, and then sectioned into thin specimens (70 nm thick) using an ultramicrotome (UC6, Leica IL). Specimens were stained with uranyl acetate and lead citrate, before being examined on a FEI Tecnai G2 Spirit BioTwin TEM (Hillsboro, OR) at an accelerating voltage of 120 kV.

Persistence assay
-----------------

The persistence assay was performed as described previously[@b6] with slight modification. Briefly, each culture was induced with 1 mM IPTG for 2 h at an OD~600~ of 0.1 (for the strain carrying the empty vector and GhoS-producing strain) or 0.5 (for ArT- or MqsR-producing strains). After adjusting each culture to an OD~600~ of 1.0, cells were exposed to 100 μg/mL ampicillin for 3 h. Cell viability before and after ampicillin treatment was determined by applying 10 μL drops in serial dilutions[@b56] on LB-chloramphenicol agar, and growing at 37°C for 24 h. Three independent cultures per strain were evaluated.

Bacterial two-hybrid analysis
-----------------------------

*In vivo* protein interactions were assessed using a bacterial two-hybrid approach based on functional reconstitution of adenylate cyclase (CyaA) activity of *Bordetella pertussis* in an *E. coli cya*^−^ strain (*E. coli* BTH101, [Table 1](#t1){ref-type="table"}). The two catalytic domains of CyaA, T18 and T25, were produced from pUT18Clinker and pKT25linker, respectively. Proteins of interest (GhoS, ArT, MqsA, and ArA) were fused to the C-terminus of either T18 or T25 by cloning their coding sequence into the *Eco*RI and *Xho*I sites in the plasmids. The *ghoS* and *arT* coding sequence were amplified using primers *ghoS*-BTH-f and *ghoS*-BTH-r, while the *mqsA* and *arA* coding sequence were amplified using primers *mqsA*-BTH-f and *mqsA-*BTH-r. After co-transforming *E. coli* BTH101 with various combinations of the pUT18Clinker-based and pKT25linker-based plasmids ([Table 1](#t1){ref-type="table"}), 2 μL of each tested culture was used to streak LB-kanamycin-ampicillin agar containing 40 μg/mL 5-bromo-4-chloro-3-indolyl-β-*D*-galactopyranoside (X-gal) and IPTG at 0, 0.05, or 0.5 mM. Agar plates were incubated at 30°C for 2 days.

Western blot analysis
---------------------

Strains were grown to an OD~600~ of 0.6 to 0.9, then 1 mM IPTG was added to induce protein production for 5 h. Cells were centrifuged (13,000 *× g*, 2 min) and sonicated, and the total proteins were resolved via 18% Tris-tricine-SDS gels. A Western blot was performed with primary antibodies raised against a His tag (Cell Signaling Technology, Danvers, MA) or a FLAG tag (Thermo Scientific, Waltham, MA), and horseradish peroxidase-conjugated goat anti-mouse secondary antibodies (Cell Signaling Technology). Blotted proteins were detected using the chemiluminescence reagents from the SuperSignal West-Pico Chemiluminescence kit (Thermo Scientific).
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![Substitutions M31L and L25I convert GhoS to a toxin.\
All plasmids were expressed in *E. coli* BW25113 Δ*ghoS*. (a) Cells producing either GhoS-M31L, GhoS-L25I, or ArT (M31L + L25I) have reduced growth on LB agar containing 1 mM IPTG (upper right) after 24 h. All strains grew on LB agar without IPTG (upper left). Note that native GhoS does not confer toxicity to cells. The positive control, GhoT, is the membrane toxin from the GhoS/GhoT system. pCA24N denotes empty vector. (b) Reduced growth of cells expressing ArT in liquid LB after the addition of 1 mM IPTG (added at t = 0 h). Error bars indicate s.e.m. (n = 3). (c) Mutations M31L and L25I (green) mapped to the structure of GhoS (pdb: 2llz). Residues in blue denote conserved residues in GhoS.](srep04807-f1){#f1}

![ArT-producing cells show "ghost"-like phenotype.\
(a) Appearance of cells producing GhoS, ArT, and GhoT under phase contrast at 1,000× magnification (oil immersion). GhoS: BW25113/pCA24N-*ghoS*, ArT: BW25113/pCA24N-*arT*, and GhoT: BW25113/pCA24N-*ghoT*. (b) Localization of GFP-tagged GhoS, ArT, and GhoT using epifluorescence microscopy. Note the "ghost"-like phenotype in cells producing ArT, and the true "ghost" cells in GhoT-expressing cells. GhoS: BW25113/pCA24N-*ghoS*(GFP^+^), ArT: BW25113/pCA24N-*arT*(GFP^+^), and GhoT: BW25113/pCA24N-*ghoT*(GFP^+^). Scale bars denote 5 µm.](srep04807-f2){#f2}

![TEM images of cells producing GhoS, ArT, and GhoT.\
(a) to (c): Longitudinal sections of BW25113/pCA24N-*ghoS*, BW25113/pCA24N-*arT*, and BW25113/pCA24N-*ghoT*, respectively. (d) to (f): Cross-sectional views of BW25113/pCA24N-*ghoS*, BW25113/pCA24N-*arT*, and BW25113/pCA24N-*ghoT*. Scale bars denote 0.5 µm. Red arrow indicates internal translucent areas, and green circles show condensed areas at the poles.](srep04807-f3){#f3}

![Mutated MqsA variants abolish the toxicity of GhoS-M31L.\
All plasmids were expressed in *E. coli* BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^ using a single plasmid system that produces both the toxin and antitoxin (a) Growth of cells producing GhoS-M31L and different MqsA variants on LB agar with and without IPTG. Note that native MqsA does not abolish the toxicity of GhoS-M31L. (b) Growth of cells expressing GhoS-M31L and different MqsA variants in liquid LB after the addition of 1 mM IPTG (added at t = 0 h). Error bars indicate s.e.m. (*n* = 3). (c) Residues K2, H7, D51, and M54 (shown as pink sticks) mapped to the structure of MqsA (pdb: 3gn5). These residues were substituted more than once among the six selected MqsA variants. Green sphere denotes zinc ion. Empty: pCA24N, GhoSM31L-MqsA: pCA24N-*ghoS*-M31L-*mqsA*, GhoT: pCA24N-*ghoT*, MQIP1: pCA24N-*ghoS*-M31L-*mqsA*-V12A-M54L-K58N-K76Q, MQIP7: pCA24N-*ghoS*-M31L-*mqsA-*H7L-P19S-V28A-M54I-K80E-H110Y, MQIP15: pCA24N-*ghoS-*M31L-*mqsA*-H7L-I15N-H33L-V75E, MQIP20: pCA24N-*ghoS*-M31L-*mqsA-*K2E-MP22-F22L-C37S-D51N-F60L, MP22: pCA24N-*ghoS*-M31L-*mqsA*-F22L-C37S-D51N-F60L, MP38: pCA24N-*ghoS*-M31L-*mqsA*-K2E-Q8L.](srep04807-f4){#f4}

![ToxI variants abolished the toxicity of ArT.\
All plasmids were expressed in *E. coli* BW25113 Δ*ghoS* using a single plasmid system that produces both the toxin and antitoxin. (a) Growth of cells producing ArT and different ToxI variants on LB agar with and without IPTG. (b) Growth of cells expressing ArT and different ToxI variants in LB after the addition of 1 mM IPTG (added at t = 0 h). Error bars indicate s.e.m. (n = 3). Empty: pCA24N, toxI-ArT: pCA24N-*toxI-arT*, GhoT: pCA24N-*ghoT*, TPP25: pCA24N-*toxI*-T36C-C73T-A248G*-arT*, TPPA12: pCA24N-*toxI*-T9A-T23A-A134T-T167G-T180C-A182T-A245T*-arT*, TPPA14: pCA24N-*toxI*-T10A-T116G-A250G*-arT*, TPPA17: pCA24N-*toxI*-A34G-A56T-A62T-A182G-T197C*-arT*, TPPB9: pCA24N-*toxI*-A1C-A62T*-arT*, TPPB14: pCA24N-*toxI*-T188A*-arT*.](srep04807-f5){#f5}

![ArT increases cell persistence to ampicillin.\
Persistence of *E. coli* BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^ harboring different plasmids after ampicillin (100 μg/mL) treatment for 3 h. Empty: pCA24N, GhoS, pCA24N-*ghoS*, ArT: pCA24N-*arT*, MqsR: pCA24N-*mqsR*.](srep04807-f6){#f6}

###### Bacterial strains and plasmids used in this study. Km^R^, Ap^R^, and Cm^R^ denotes kanamycin, ampicillin, and chloramphenicol resistance, respectively

  Strains or plasmids                                                                  Description                                                                    Source
  --------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------
  ***E. coli*** **K-12**                                                                                                                                                 
  BTH101                                                F^−^, *cya-99* *araD139 galE15 galK16 rpsL1 (Str ^r^)* *hsdR2 mcrA1 mcrB1*                          (Gully and Bouveret, 2006)
  BW25113                                                 *rrnB3* Δ*lacZ4787 hsdR514* Δ(*araBAD*)*567* Δ(*rhaBAD*)*568 rph*-*1*                               (Baba *et al.*, 2006)
  BW25113 Δ*ghoS*                                                                BW25113 Δ*ghoS* Ω Km^R^                                                      (Baba *et al.*, 2006)
  BW25113 Δ*ghoS* Δ*mqsRA*ΩKm^R^                                          BW25113 Δ*ghoS::frt* Δ*mqsRA* Ω Km^R^                                               (Wang *et al.*, 2013)
  BW25113 Δ*ghoS* Δ*mqsRA* ΔKm^R^                                           BW25113 Δ*ghoS::frt* Δ*mqsRA::frt*                                                      This study
  BW25113 Δ*ghoT*                                                                BW25113 Δ*ghoT* Ω Km^R^                                                      (Baba *et al.*, 2006)
  BW25113 Δ*mqsRA*                                                               BW25113 Δ*mqsRA* ΔKm^R^                                                       (Kim *et al.*, 2010)
  **Plasmids**                                                                                                                                                           
  pBAD-*mqsA*                                                         Ap^R^, pBR322 *ori*, P*~ARA~*::*mqsA-flag*^+^                                                 This study
  pBAD-*arA*                                                           Ap^R^, pBR322 *ori*, P*~ARA~*::*arA-flag*^+^                                                 This study
  pBAD-*myc*-His B                                                    Ap^R^, pBR322 *ori*, P*~ARA~*::*myc-His~6~*^+^                                                Life Tech.
  pBR-plac                                                                  Ap^R^, pBR322 *ori*, P*~LlacO-1~*                                             (Guillier and Gottesman, 2006)
  pBR-plac-*toxI*                                                      Ap^R^, pBR322 *ori*, P*~LlacO-1~*::*toxI*^+^                                                 This study
  pBS(Kan)-*mqsA*                                                                Km^R^; P*~lac~*::*mqsA*                                                       (Kim *et al.*, 2010)
  pCA24N                                                                             Cm^R^; *lacI*^q^                                                       (Kitagawa *et al.*, 2005)
  pCA24N-*arA*                               Cm^R^; *lacI*^q^ P*~T5-lac~*::*arA-flag*^+^ with two *mqsRA* palindromes between *lacO* and RBS                        This study
  pCA24N-*arT*                              Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-arT*^+^ with two *mqsRA* palindromes between *lacO* and RBS                       This study
  pCA24N-*arT-arA*                   Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-arT*^+^, *arA-flag*^+^ with two *mqsRA* palindromes between *lacO* and RBS               This study
  pCA24N-*arT* (GFP^+^)                                             Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-arT-gfp*^+^                                               This study
  pCA24N-*ghoS*                                                       Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoS*^+^                                        (Kitagawa *et al.*, 2005)
  pCA24N-*ghoS*(GFP^+^)                                            Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoS*-*gfp*^+^                                     (Kitagawa *et al.*, 2005)
  pCA24N-*ghoS-L25I*                   Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoS*^+^ with TTA (121-123 nt relative to start codon) mutated to ATA                  This study
  pCA24N-*ghoS*-*M31L*                 Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoS*^+^ with ATG (139-141 nt relative to start codon) mutated to TTG                  This study
  pCA24N-*ghoS*-*M31L-mqsA*                                  Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoS^+^-M31L-mqsA-flag*^+^                                       This study
  pCA24N-*ghoT*                                                       Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoT*^+^                                        (Kitagawa *et al.*, 2005)
  pCA24N-*ghoT*(GFP^+^)                                            Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-ghoT*-*gfp*^+^                                     (Kitagawa *et al.*, 2005)
  pCA24N-*mqsR*                                                       Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~-mqsR*^+^                                        (Kitagawa *et al.*, 2005)
  pCA24N-*toxI*-*arT*                                    Cm^R^; *lacI*^q^ P*~T5-lac~*::*His~6~*-*arT*^+^, P*~LlacO-1~*::*toxI*^+^                                   This study
  pCP20                                                            Ap^R^, Cm^R^; FLP^+^, λ *c*I857^+^, λ *p~R~* Rep^ts^                                 (Cherepanov and Wackernagel, 1995)
  pKT25linker                                                             Km^R^, p15A *ori*, P*~lac~*::*T25*^+^                                             (Gully and Bouveret, 2006)
  pKT25linker-*ghoS*                                                    Km^R^, p15A *ori*, P*~lac~*::*T25-ghoS*^+^                                                  This study
  pKT25linker-*arT*                                                     Km^R^, p15A *ori*, P*~lac~*::*T25-arT*^+^                                                   This study
  pKT25linker-*zip*                                                     Km^R^, p15A *ori*, P*~lac~*::*T25-zip*^+^                                           (Gully and Bouveret, 2006)
  pUT18Clinker                                                            Ap^R^, ColE1 *ori*, P*~lac~*::*T18*^+^                                            (Gully and Bouveret, 2006)
  pUT18Clinker-*mqsA*                                                  Ap^R^, ColE1 *ori*, P*~lac~*::*T18-mqsA*^+^                                                  This study
  pUC18Clinker-*arA*                                                    Ap^R^, ColE1 *ori*, P*~lac~*::*T18-arA*^+^                                                  This study
  pUT18Clinker-*zip*                                                    Ap^R^, ColE1 *ori*, P*~lac~*::*T18-zip*^+^                                          (Gully and Bouveret, 2006)

*arA* refers to *mqsA* with TTC (64-66 nt relative to start codon) mutated to CTC, TGT (109-111 nt relative to start codon) mutated to AGT, GAT (151-153 nt relative to start codon) mutated to AAT, TTT (178-180 nt relative to start codon) mutated to CTT. *arT* refers to *ghoS* with TTA (121-123 nt relative to start codon) mutated to ATA, and ATG (139-141 nt relative to start codon) mutated to TTG.
